Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going

• Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Parra-Lara, Luis Gabriel, Martínez-Arboleda, Juan José, Rosso, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. 2020
Materias:
SARS CoV-2 Dispatches
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328586/
https://www.ncbi.nlm.nih.gov/pubmed/32622008
http://dx.doi.org/10.1016/j.jgar.2020.06.016
Descripción
Sumario:• Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combination of AZM and HCQ should be decided with caution due serious cardiac adverse effects. • Currently, 21 clinical trials are being carried out on the use of AZM in COVID-19.

Ejemplares similares